
3Scan
Offers automated microscopy services and supporting software for the 3D analysis of cells, tissues, and organs.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor | €0.0 | round |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | Merger | |
Total Funding | 000k |











Related Content
3Scan, now part of Strateos, operates in the biotechnology sector, providing advanced robotic cloud lab services that accelerate biological research and development. The company specializes in automated tissue imaging and experimentation, serving clients such as pharmaceutical companies, research institutions, and biotech firms. By leveraging robotic systems and cloud-based platforms, 3Scan enables high-throughput and precise biological experiments, significantly reducing the time and cost associated with traditional laboratory work. Their business model revolves around offering subscription-based access to their cloud lab services, as well as custom project-based solutions. Revenue is generated through service fees, collaborations, and grants. The company has established notable partnerships with industry leaders like Ginkgo Bioworks and Eli Lilly, further solidifying its position in the market.
Keywords: robotic cloud lab, tissue imaging, biological research, automation, biotechnology, pharmaceutical, research institutions, high-throughput, cloud-based, partnerships.